Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976410 | 0.99 | HPGD (0.45) | HPGDKDRMCHR1KCNH2EPHX2 | |
| SCHEMBL2973369 | 0.92 | EPHX2 (0.52) | HPGDEPHX2L3MBTL1SCN9AABL1 | |
| SCHEMBL2971081 | 0.89 | SLC6A5 (0.42) | HPGDSLC6A5 | |
| SCHEMBL4065692 | 0.88 | KDR (0.43) | HPGDKDRMCHR1KCNH2SCN9A | |
| SCHEMBL1380313 | 0.88 | MAPT (0.50) | HPGDEPHX2GLAL3MBTL1 | |
| SCHEMBL4069255 | 0.88 | MCHR1 (0.42) | HPGDKDRMCHR1KCNH2SCN9A | |
| SCHEMBL1380711 | 0.87 | MEN1 (0.51) | HPGDEPHX2GLAL3MBTL1 | |
| SCHEMBL2970729 | 0.86 | HPGD (0.47) | HPGDEPHX2TRPV1ABL1 | |
| SCHEMBL2961360 | 0.85 | HPGD (0.44) | HPGDKCNH2EPHX2 | |
| SCHEMBL2973781 | 0.85 | ALOX5 (0.47) | HPGDMCHR1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767673-B2 | N-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | claimed |
| EP-1658289-B1 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARM INC (US) | 2009-03-18 | — | — | EP | claimed |
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | claimed |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | CASTELHANO ARLINDO L | 2008-09-11 | — | — | US | claimed |
| JP-2007502822-A | — | — | 2007-02-15 | — | — | JP | claimed |
| EP-1658289-A2 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | CASTELHANO ARLINDO L | 2006-02-16 | — | — | US | claimed |
| WO-2005021544-A2 | N3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-7767673-B2 | N-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1658289-B1 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARM INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-7442709-B2 | N3-substituted imidazopyridine c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | CASTELHANO ARLINDO L | 2008-09-11 | — | — | US | disclosed |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | CASTELHANO ARLINDO L | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062275-A1 | N-Substituted Imidazopyridine c-Kit Inhibitors | KIT, ABL1, CHUK | HPGD 666/4885KDR 53/4885MCHR1 3735/4885 |
| US-20080221153-A9 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS | KIT, ABL1, CHUK | HPGD 1281/4885KDR 37/4885MCHR1 3444/4885 |
| US-20060035921-A1 | N3-substituted imidazopyridine c-Kit inhibitors | KIT, ABL1, CHUK | HPGD 1281/4885KDR 37/4885MCHR1 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.